Nachrichten zu Plus Therapeutics Registered (Old)

Um die volle Funktionalität der Webseite nutzen zu können, müssen Sie JavaScript in ihrem Browser aktivieren.

DAX19.102,25+0,42 %

Gold2.619,79-0,91 %

Öl (Brent)77,55-4,46 %

Dow Jones42.078,76+0,32 %

US Tech 10020.105,31+1,54 %

EUR/USD1,09785+0,06 %

Top 15 der gesamten Suchanfragen der letzten 7 Tage

Login

Plus Therapeutics Registered (Old) Aktie

Aktie

ISIN: US72941H4002 WKN: A2PPX6 Land Flagge US

USA

Zur Watchlist hinzufügen Zum Portfolio hinzufügen

Zum Portfolio hinzufügen

0,2598

USD

0,00 %

Letzter Kurs 29.04.23 NYSE

Plus Therapeutics Registered (Old) Aktie kaufen

Neueste Nachrichten

Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual Meeting 01.10.24 · globenewswire · Plus Therapeutics Registered (Old)
Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of Neurological Surgeons Annual Meeting 18.09.24 · globenewswire · Plus Therapeutics Registered (Old)
Plus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference 04.09.24 · globenewswire · Plus Therapeutics Registered (Old)
Plus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights 14.08.24 · globenewswire · Plus Therapeutics Registered (Old)
Plus Therapeutics Presents Positive Clinical Trial Results at the 2024 SNO/ASCO CNS Metastases Conference 13.08.24 · globenewswire · Plus Therapeutics Registered (Old)
Plus Therapeutics Presents Positive Interim ReSPECT-LM Phase 1 Data for Leptomeningeal Metastases at 2024 SNO/ASCO CNS Metastases Conference 12.08.24 · globenewswire · Plus Therapeutics Registered (Old)
Plus Therapeutics to Announce Second Quarter Financial Results and Host Conference Call on August 14, 2024 08.08.24 · globenewswire · Plus Therapeutics Registered (Old)
Plus Therapeutics Showcases Leptomeningeal Metastases Programs at 2024 SNO/ASCO Conference 25.07.24 · globenewswire · Plus Therapeutics Registered (Old)
Plus Therapeutics to Present at the Gordon Research Conference Radionuclide Theranostics for the Management of Cancer 02.07.24 · globenewswire · Plus Therapeutics Registered (Old)
Plus Therapeutics Expands Management Team and Reports $3.3M Advance Payment from CPRIT 07.06.24 · globenewswire · Plus Therapeutics Registered (Old)
Plus Therapeutics Announces New Employment Inducement Grants 17.05.24 · globenewswire · Plus Therapeutics Registered (Old)
Plus Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights 15.05.24 · globenewswire · Plus Therapeutics Registered (Old)

1
2
…
3

Meistgelesen

30 Tage
12 Monate

Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of ... 588 Leser
Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological ... 100 Leser

Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of ... 588 Leser
Plus Therapeutics Presents Positive Clinical Trial Results at the 2024 SNO/ASCO CNS Metastases ... 504 Leser
Plus Therapeutics to Announce Second Quarter Financial Results and Host Conference Call on August ... 484 Leser
Plus Therapeutics to Announce First Quarter Financial Results and Host Conference Call on May 15, ... 460 Leser
Plus Therapeutics Provides Highlights Regarding Leptomeningeal Metastases Acquisition and Topline ... 400 Leser
Plus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights 384 Leser
Plus Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights 292 Leser
Plus Therapeutics Presents Positive Interim ReSPECT-LM Phase 1 Data for Leptomeningeal Metastases ... 240 Leser
Plus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference 196 Leser
Plus Therapeutics to Announce Third Quarter 2023 Financial Results and Host Conference Call on ... 176 Leser